Scatter-factor and semaphorin receptors: cell signalling for invasive growth (original) (raw)

• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  CAS PubMed Google Scholar
• Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342–348 (2001).
  Article CAS PubMed Google Scholar
• Bissell, M. J. & Radisky, D. Outting tumours in context. Nature Rev. Cancer 1, 46–54 (2001).
  CAS Google Scholar
• Stoker, M. Gherardi, E., Perryman, M. & Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell motility. Nature 327, 239–242 (1987).
  CAS PubMed Google Scholar
• Nakamura, T. et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440–443 (1989).
  CAS PubMed Google Scholar
• Montesano, R., Matsumoto, K., Nakamura, T. & Orci, L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67, 901–908 (1991).
  CAS PubMed Google Scholar
• Naldini, L. et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the Met receptor. EMBO J. 10, 2867–2878 (1991).
  CAS PubMed PubMed Central Google Scholar
• Skeel, A. et al. Macrophage stimulating protein: purification, partial amino acid sequence, and cellular activity. J. Exp. Med. 173, 1227–1234 (1991).
  CAS PubMed Google Scholar
• Giordano, S., Ponzetto, C., Di Renzo, M. F., Cooper, C. S. & Comoglio, P. M. Tyrosine kinase receptor indistinguishable from the c-Met protein. Nature 339, 155–156 (1989).
  CAS PubMed Google Scholar
• Gaudino, G. et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J. 13, 3524–3532 (1994).
  CAS PubMed PubMed Central Google Scholar
• Wang, M. H. et al. Identification of the RON gene product as the receptor for the human macrophage stimulating protein. Science 266, 117–119 (1994).
  CAS PubMed Google Scholar
• Kolodkin, A. L., Matthes, D. J. & Goodman, C. S. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 75, 1389–1399 (1993).
  CAS PubMed Google Scholar
• Winberg, M. L. et al. Plexin A is a neuronal semaphorin receptor that controls axon guidance. Cell 95, 903–916 (1998).
  CAS PubMed Google Scholar
• Tamagnone, L. et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 99, 71–80 (1999).
  Article CAS PubMed Google Scholar
• Tamagnone, L. & Comoglio, P. M. Signalling by semaphorin receptors: cell guidance and beyond. Trends Cell Biol. 10, 377–383 (2000).
  Article CAS PubMed Google Scholar
• Montesano, R., Schaller, G. & Orci, L. Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors. Cell 66, 697–711 (1991).
  CAS PubMed Google Scholar
• Berdichevsky, F., Alford, D., Souza B. & Taylor-Papadimitriou, J. Branching morphogenesis of human mammary epithelial cells in collagen gels. J. Cell Sci. 107, 3557–3568 (1994).
  CAS PubMed Google Scholar
• Soriano, J. V., Pepper, M. S., Nakamura, T., Orci, L. & Montesano, R. Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary gland epithelial cells. J. Cell Sci. 108, 413–430 (1995).
  CAS PubMed Google Scholar
• Niemann, C. et al. Reconstitution of mammary gland development in vitro: requirement of c-Met and c-ErbB2 signaling for branching and alveolar morphogenesis. J. Cell Biol. 143, 533–545 (1998).Shows that HGF promotes the formation of branched tubules in mouse mammary epithelial cells that are cultured in matrigel, as well as in human mammary carcinoma tissue, in explant culture. The same morphogenetic response can be observed following transfection of GAB1, MET's main intracellular substrate.
  CAS PubMed PubMed Central Google Scholar
• Brinkmann, V., Foroutan, H., Sachs, H., Weidner, K. M. & Birchmeier, W. Hepatocyte growth factor/scatter factor induces a variety of tissue specific morphogenic programs in epithelial cells. J. Cell Biol. 131, 1573–1586 (1995).
  CAS PubMed Google Scholar
• Bussolino, F. et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 119, 629–640 (1992).
  CAS PubMed Google Scholar
• Schmidt, C. et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373, 699–702 (1995).
  CAS PubMed Google Scholar
• Uehara, Y. et al. Placental defect and embryonal lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373, 702–705 (1995).
  CAS PubMed Google Scholar
• Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A. & Birchmeier, C. Essential role for the c-Met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768–771 (1995).
  CAS PubMed Google Scholar
• Yu, T. W. & Bargmann, C. I. Dynamic regulation of axon guidance. Nature Neurosci. 4, 1169–1176 (2001).
  CAS PubMed Google Scholar
• Ebens, A. et al. Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons. Neuron 17, 1157–1172 (1996).
  CAS PubMed Google Scholar
• Wong, V. et al. Hepatocyte growth factor promotes motor neuron survival and synergizes with ciliary neurotrophic factor. J. Biol. Chem. 272, 5187–5191 (1997).
  CAS PubMed Google Scholar
• Yamamoto, Y. et al. Hepatocyte growth factor (HGF/SF) is a muscle-derived survival factor for a subpopulation of embryonic motoneurons. Development 124, 2903–2913 (1997).
  CAS PubMed Google Scholar
• Maina, F., Hilton, M. C., Ponzetto, C., Davies, A. M. & Klein, R. Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons. Genes Dev. 11, 3341–3350 (1997).
  CAS PubMed PubMed Central Google Scholar
• Maina, F. et al. Multiple roles for hepatocyte growth factor in sympathetic neuron development. Neuron 20, 835–846 (1998).
  CAS PubMed Google Scholar
• Luo, Y., Raible, D. & Raper, J. A. Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 75, 217–227 (1993).
  CAS PubMed Google Scholar
• Wong, J. T., Wong, S. T. & O'Connor, T. P. Ectopic semaphorin-1a functions as an attractive guidance cue for developing peripheral neurons. Nature Neurosci. 2, 798–803 (1999).
  CAS PubMed Google Scholar
• de Castro, F., Hu, L., Drabkin, H., Sotelo, C. & Chedotal, A. Chemoattraction and chemorepulsion of olfactory bulb axons by different secreted semaphorins. J. Neurosci. 19, 4428–4436 (1999).
  CAS PubMed PubMed Central Google Scholar
• Polleux, F., Morrow, T. & Ghosh, A. Semaphorin 3A is a chemoattractant for cortical apical dendrites. Nature 404, 567–573 (2000).
  CAS PubMed Google Scholar
• Miao, H. Q. et al. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J. Cell Biol. 146, 233–242 (1999).
  CAS PubMed PubMed Central Google Scholar
• Cooper, C. S. et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311, 29–33 (1984).
  CAS PubMed Google Scholar
• Rong, S., Segal, S., Anver, M., Resau, J. H. & Vande Woude, G. F. Invasiveness and metastasis of NIH3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl Acad. Sci. USA 91, 4731–4735 (1994).
  CAS PubMed PubMed Central Google Scholar
• Bellusci, S. et al. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 9, 1091–1099 (1994).
  CAS PubMed Google Scholar
• Jeffers, M., Rong, S., Anver, M. & Vande Woude, G. F. Autocrine hepatocyte growth factor/scatter factor signalling induces transformation and the invasive/metastatic phenotype in C127 cells. Oncogene 13, 853–861 (1996).
  CAS PubMed Google Scholar
• Meiners, S., Brinkmann, V., Naundorf, H. & Birchmeier, W. Role of morphogenetic factors in metastasis of mammary carcinoma cells. Oncogene 16, 9–20 (1998).
  CAS PubMed Google Scholar
• Liang, T. J., Reid, A. E., Xavier, R., Cardiff, R. D. & Wang, T. C. Transgenic expression of Tpr–Met oncogene leads to development of mammary hyperplasia and tumors. J. Clin. Invest. 97, 2872–2877 (1996).
  CAS PubMed PubMed Central Google Scholar
• Jeffers, M. et al. The mutationally activated Met receptor mediates motility and metastasis. Proc. Natl Acad. Sci. USA 95, 14417–14422 (1998).
  CAS PubMed PubMed Central Google Scholar
• Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J. & Bishop, M. J. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153, 1023–1034 (2001).The first in vivo demonstration that transgenic overexpression of wild-type Met in hepatocytes of mice allows HGF-independent activation of the receptor, leading to development of hepatocellular carcinomas. Inactivation of the transgene results in regression of even highly advanced tumours.
  CAS PubMed PubMed Central Google Scholar
• Takayama, H. et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl Acad. Sci. USA 94, 701–706 (1997).
  CAS PubMed PubMed Central Google Scholar
• Otsuka, T. et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 58, 5157–5167 (1998).
  CAS PubMed Google Scholar
• Ferracini, R. et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10, 739–749 (1995).
  CAS PubMed Google Scholar
• Ferracini, R. et al. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 12, 1697–1705 (1996).
  CAS PubMed Google Scholar
• Scotlandi, K. et al. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am. J. Pathol. 149, 1209–1219 (1996).
  CAS PubMed PubMed Central Google Scholar
• Di Renzo, M. F. et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7, 2549–2553 (1992).
  CAS PubMed Google Scholar
• Di Renzo, M. F. et al. Overexpression of the MET/HGF receptor in ovarian cancer. Int. J. Cancer 58, 658–662 (1994).
  CAS PubMed Google Scholar
• Di Renzo, M. F., Poulsom, R., Olivero, M., Comoglio, P. M. & Lemoine, N. R. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. 55, 1129–1138 (1995).
  CAS PubMed Google Scholar
• Humphrey, P. A. et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. 147, 386–396 (1995).
  CAS PubMed PubMed Central Google Scholar
• Natali, P. G. et al. Overexpression of the MET/HGF receptor in renal cell carcinomas. Int. J. Cancer 69, 212–217 (1996).
  CAS PubMed Google Scholar
• Ruco, L. et al. Expression of Met protein in thyroid tumours. J. Pathol. 180, 266–270 (1996).
  CAS PubMed Google Scholar
• Tuck, A. B., Park, M., Sterns, E. E., Boag, A. & Elliott, B. E. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am. J. Pathol. 148, 225–232 (1996).
  CAS PubMed PubMed Central Google Scholar
• Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H. & Okamoto, E. Expression of hepatocyte growth factor and its receptor, the c-Met proto-oncogene, in hepatocellular carcinoma. Hepatology 25, 619–623 (1997).
  CAS PubMed Google Scholar
• Jin, L. et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 79, 749–760 (1997).
  CAS PubMed Google Scholar
• Toniguchi, K. et al. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-Met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82, 2112–2122 (1998).
  Google Scholar
• Porte, H. et al. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin. Cancer Res. 4, 1375–1382 (1998).
  CAS PubMed Google Scholar
• Zanetti, A. et al. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. J. Pathol. 186, 287–291 (1998).
  CAS PubMed Google Scholar
• Camp, R. L., Rimm, E. B. & Rimm, D. L. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86, 2259–2265 (1999).
  CAS PubMed Google Scholar
• Chen, B. K. et al. Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic state. Pathol. Res. Pract. 195, 427–433 (1999).
  CAS PubMed Google Scholar
• Tavian, D. et al. U-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int. J. Cancer 87, 644–649 (2000).
  CAS PubMed Google Scholar
• Wielenga, V. J. et al. Expression of c-MET and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. Am. J. Pathol. 157, 1563–1573 (2000).
  CAS PubMed PubMed Central Google Scholar
• Ramirez, R. et al. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (c-MET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin. Endocrinol. 53, 635–644 (2000).
  CAS Google Scholar
• Edakuni, G., Sasatomi, E., Satoh, T., Tokunaga, O. & Miyazaki, K. Expression of the hepatocyte growth factor/ c-Met pathway is increased at the cancer front in breast carcinoma. Pathol. Int. 51, 172–178 (2001).
  CAS PubMed Google Scholar
• Tapper, J. et al. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet. Cytogenet. 128, 1–6 (2001).
  CAS PubMed Google Scholar
• Huang, T. J., Wang, J. Y., Lin, S. R., Lian, S. T. & Hsieh, J. S. Overexpression of the c-Met protooncogene in human gastric carcinoma — correlation to clinical features. Acta Oncol. 40, 638–643 (2001).
  CAS PubMed Google Scholar
• Takeo, S. et al. Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridisation analysis. Cancer Genet. Cytogenet. 130, 127–132 (2001).
  CAS PubMed Google Scholar
• Morello, S. et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J. Cell. Physiol. 189, 285–290 (2001).
  CAS PubMed Google Scholar
• Huang, Y. et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc. Natl Acad. Sci. USA 98, 15044–15049 (2001).
  CAS PubMed PubMed Central Google Scholar
• Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet. 16, 68–73 (1997).The first report of naturally occurring oncogenic mutations of MET in humans. Missense mutations were identified that are located in the tyrosine kinase domain of the MET gene in the germ line of patients who suffer from hereditary papillary renal-cell carcinomas and in a subset of sporadic papillary renal carcinomas.
  CAS PubMed Google Scholar
• Fischer, J. et al. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 17, 733–739 (1998).
  CAS PubMed Google Scholar
• Schmidt, L. et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18, 2343–2350 (1999).
  CAS PubMed Google Scholar
• Olivero, M. et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int. J. Cancer 82, 640–643 (1999).
  CAS PubMed Google Scholar
• Park, W. S. et al. Somatic mutations in the kinase domain of the MET/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 59, 307–310 (1999).
  CAS PubMed Google Scholar
• Lee, J. H. et al. A novel germ line juxtamembrane MET mutation in human gastric cancer. Oncogene 19, 4947–4953 (2000).
  CAS PubMed Google Scholar
• Jeffers, M. et al. Activating mutations for the MET tyrosine kinase receptor in human cancer. Proc. Natl Acad. Sci. USA 94, 11445–11450 (1997).
  CAS PubMed PubMed Central Google Scholar
• Michieli, P. et al. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18, 5221–5231 (1999).Shows that the transforming potential displayed by mutant forms of MET found in human cancer is not only sensitive to, but entirely contingent on, the presence of HGF. This finding indicates that mutant MET-driven tumour development relies on local availability and tissue distribution of active HGF and provides proof-of-concept for the treatment of MET-dependent neoplasms by HGF antagonists.
  CAS PubMed Google Scholar
• Yao, Y. et al. Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. Am. J. Pathol. 149, 1707–1717 (1996).
  CAS PubMed PubMed Central Google Scholar
• Di Renzo, M. F. et al. Overexpression and amplification of the MET/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1, 147–154 (1995).
  CAS PubMed Google Scholar
• Di Renzo, M. F. et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19, 1547–1555 (2000).The first report of a direct involvement of MET in tumour metastasis in humans. Neoplastic cells that harbour activating mutations of the MET gene undergo clonal expansion during the metastatic spreading of head and neck squamous-cell carcinomas.
  CAS PubMed Google Scholar
• Eagles, G. et al. Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients. Br. J. Cancer 73, 377–381 (1996).
  CAS PubMed PubMed Central Google Scholar
• Nagafuchi, A. Molecular architecture of adherens junctions. Curr. Opin. Cell Biol. 13, 600–603 (2001).
  CAS PubMed Google Scholar
• Tannapfel, A., Yasui, W., Yokozaki, H., Wittekind, C. & Tahara, E. Effect of hepatocyte growth factor on the expression of E- and P-cadherin in gastric carcinoma cell lines. Virchows Arch. 425, 139–144 (1994).
  CAS PubMed Google Scholar
• Miura, H. et al. Effects of hepatocyte growth factor on E-cadherin-mediated cell–cell adhesion in DU145 prostate cancer cells. Urology 58, 1064–1069 (2001).
  CAS PubMed Google Scholar
• Balkovetz, D. F., Pollack, A. L. & Mostov, K. E. Hepatocyte growth factor alters the polarity of Madin–Darby canine kidney cell monolayers. J. Biol. Chem. 272, 3471–3477 (1997).
  CAS PubMed Google Scholar
• Balkovetz, D. F. & Sambandam, V. Dynamics of E-cadherin and γ-catenin complexes during dedifferentiation of polarized MDCK cells. Kidney Int. 56, 910–921 (1999).
  CAS PubMed Google Scholar
• Davies, G., Jiang, W. G. & Mason, M. D. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell–cell dissociation and in vitro invasion. Clin. Cancer Res. 7, 3289–3297 (2001).
  CAS PubMed Google Scholar
• Shibamoto, S. et al. Tyrosine phosphorylation of β-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. Cell Adhes. Commun. 1, 295–305 (1994).
  CAS PubMed Google Scholar
• Frisch, S. M. & Screaton, R. A. Anoikis mechanisms. Curr. Opin. Cell Biol. 13, 555–562 (2001).
  CAS PubMed Google Scholar
• Plow, E. F., Haas, T. A., Zhang, L., Loftus, J. & Smith, J. W. Ligand binding to integrins. J. Biol. Chem. 275, 21785–21788 (2000).
  CAS PubMed Google Scholar
• Woods, A. & Couchman, J. R. Integrin modulation by lateral association. J. Biol. Chem. 275, 24233–24236 (2000).
  CAS PubMed Google Scholar
• Nebe, B., Sanftleben, H., Pommerenke, H., Peters, A. & Rychly, J. Hepatocyte growth factor enables enhanced integrin-cytoskeleton linkage by affecting integrin expression in subconfluent epithelial cells. Exp. Cell Res. 243, 263–273 (1998).
  CAS PubMed Google Scholar
• Liang, C. C. & Chen, H. C. Sustained activation of extracellular signal-regulated kinase stimulated by hepatocyte growth factor leads to integrin α2 expression that is involved in cell scattering. J. Biol. Chem. 276, 21146–21152 (2001).
  CAS PubMed Google Scholar
• Trusolino, L. et al. Growth factor-dependent activation of αvβ3 integrin in normal epithelial cells: implications for tumor invasion. J. Cell Biol. 142, 1145–1156 (1998).
  CAS PubMed PubMed Central Google Scholar
• Trusolino, L. et al. HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J. 14, 1629–1640 (2000).
  CAS PubMed Google Scholar
• Brooks, P. C. et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ Cell 85, 683–693 (1996).
  CAS PubMed Google Scholar
• Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W. G. & Quaranta, V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277, 225–228 (1997).
  CAS PubMed Google Scholar
• Rosenthal, E. L. et al. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res. 58, 5221–5230 (1998).
  CAS PubMed Google Scholar
• Nabeshima, K. et al. Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor. Cancer Res. 60, 3364–3369 (2000).
  CAS PubMed Google Scholar
• Monvoisin, A. et al. Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells. Int. J. Cancer 97, 157–162 (2002).
  CAS PubMed Google Scholar
• Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 6, 389–395 (2000).
  CAS PubMed Google Scholar
• Martin-Satue, M. & Blanco, J. Identification of semaphorin E gene expression in metastatic human lung adenocarcinoma cells by mRNA differential display. J. Surg. Oncol. 72, 18–23 (1999).
  CAS PubMed Google Scholar
• Yamada, T., Endo, R., Gotoh, M. & Hirohashi, S. Identification of semaphorin E as a non-MDR drug resistance gene of human cancer. Proc. Natl Acad. Sci. USA 94, 14713–14718 (1997).
  CAS PubMed PubMed Central Google Scholar
• Christensen, C. R. et al. Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines. Cancer Res. 58, 1238–1244 (1998).
  CAS PubMed Google Scholar
• Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211–225 (2000).
  CAS PubMed Google Scholar
• Ponzetto, C. et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77, 261–271 (1994).
  CAS PubMed Google Scholar
• Pelicci, G. et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 10, 1631–1638 (1995).
  CAS PubMed Google Scholar
• Weidner, K. M. et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384, 173–176 (1996).
  CAS PubMed Google Scholar
• Gual, P. et al. Sustained recruitment of phospholipase c-γ to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 19, 1509–1518 (2000).
  CAS PubMed Google Scholar
• Maroun, C. R., Naujokas, M. A., Holgado-Madruga, M., Wong, A. J. & Park, M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 20, 8513–8525 (2000).
  CAS PubMed PubMed Central Google Scholar
• Schaeper, U. et al. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J. Cell Biol. 149, 1419–1432 (2000).
  CAS PubMed PubMed Central Google Scholar
• Boccaccio, C. et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391, 285–288 (1998).
  CAS PubMed Google Scholar
• Bardelli, A. et al. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc. Natl Acad. Sci. USA 95, 14379–14383 (1998).
  CAS PubMed PubMed Central Google Scholar
• Maina, F. et al. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell 87, 531–542 (1996).
  CAS PubMed Google Scholar
• Sachs, M. et al. Motogenic and morphogenic activity of epithelial receptor tyrosine kinases. J. Cell Biol. 133, 1095–1107 (1996).
  CAS PubMed Google Scholar
• Giordano, S. et al. A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc. Natl Acad. Sci. USA 94, 13868–13872 (1997).
  CAS PubMed PubMed Central Google Scholar
• Bardelli, A. et al. Concomitant activation of pathways downstream of Grb2 and PI3-kinase is required for MET-mediated metastasis. Oncogene 18, 1139–1146 (1999).
  CAS PubMed Google Scholar
• Trusolino, L., Bertotti, A. & Comoglio, P. M. A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth. Cell 107, 643–654 (2001).
  CAS PubMed Google Scholar
• Peschard, P. et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995–1004 (2001).A new mechanism of MET-dependent oncogenic transformation. The c-CBL adaptor protein binds a juxtamembrane tyrosine residue on MET and drives it to ubiquitin-mediated proteasomal degradation. A MET receptor in which this tyrosine is replaced by phenylalanine does not undergo polyubiquitylation and displays transforming activity in fibroblasts and epithelial cells.
  CAS PubMed Google Scholar
• Petrelli, A. et al. The endophilin/CIN85/CBL complex mediates ligand-dependent down-regulation of c-Met. Nature 416, 187–190 (2002).
  CAS PubMed Google Scholar
• Brodin, L., Low, P. & Shupliakov, O. Sequential steps in clathrin-mediated synaptic vesicle endocytosis. Curr. Opin. Neurobiol. 10, 312–320 (2000).
  CAS PubMed Google Scholar
• Winberg, M. L. et al. The transmembrane protein Off-Track associates with plexins and functions downstream of semaphorin signaling during axon guidance. Neuron 32, 53–62 (2001).
  CAS PubMed Google Scholar
• Luo, L. RHO–GTPases in neuronal morphogenesis. Nature Rev. Neurosci. 1, 173–180 (2000).
  CAS Google Scholar
• Dickson, B. J. RHO–GTPases in growth cone guidance. Curr. Opin. Neurobiol. 11, 103–110 (2001).
  CAS PubMed Google Scholar
• Rohm, B., Rahim, B., Kleiber, B., Hovatta, I. & Pueschel, A. W. The semaphorin 3A receptor may directly regulate the activity of small GTPases. FEBS Lett. 486, 68–72 (2000).
  CAS PubMed Google Scholar
• Vikis, H. G., Li, W., He, Z. & Guan, K.-L. The semaphorin receptor plexin-B1 specifically interacts with active Rac in a ligand-dependent manner. Proc. Natl Acad. Sci. USA 97, 12457–12462 (2000).
  CAS PubMed PubMed Central Google Scholar
• Driessens, M. H. et al. Plexin-B semaphorin receptors interact directly with active Rac and regulate the actin cytoskeleton by activating Rho. Curr. Biol. 11, 339–344 (2001).
  CAS PubMed Google Scholar
• Hu, H., Marton, T. F. & Goodman, C. S. Plexin B mediates axon guidance in Drosophila by simultaneously inhibiting active Rac and enhancing RhoA signalling. Neuron 32, 39–51 (2001).
  CAS PubMed Google Scholar
• Simon, M. A. Receptor tyrosine kinases: specific outcomes from general signals. Cell 103, 13–15 (2000).
  CAS PubMed Google Scholar
• Pawson, T. & Saxton, T. M. Signaling networks — do all roads lead to the same genes? Cell 97, 675–678 (1999).
  CAS PubMed Google Scholar
• Maina, F. et al. Coupling Met to specific pathways results in distinct developmental outcomes. Mol. Cell 7, 1293–1306 (2001).Addresses, in vivo , the issue of whether the specificity of tyrosine-kinase-receptor-dependent responses is determined by qualitative or quantitative differences in signalling outputs. Knockin Met mutants with optimal PI3K or Src binding motifs result in loss of function, but display different phenotypes and rescue of specific cell types, indicating that specific signalling pathways are necessary to achieve specific biological responses.
  CAS PubMed Google Scholar
• Karihaloo, A., O'Rourke, D. A., Nickel, C. H., Spokes, K. & Cantley, L. G. Differential MAPK pathways utilized for HGF- and EGF-dependent renal epithelial morphogenesis. J. Biol. Chem. 276, 9166–9173 (2001).
  CAS PubMed Google Scholar
• Boccaccio, C., Andò, M. & Comoglio, P. M. A differentiation switch for genetically modified hepatocytes. FASEB J. 16, 120–122 (2002).
  CAS PubMed Google Scholar
• Chan, A. M. et al. Identification of a competitive HGF antagonist encoded by an alternative transcript. Science 254, 1382–1385 (1991).
  CAS PubMed Google Scholar
• Hartmann, G. et al. A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. Proc. Natl Acad. Sci. USA 89, 11574–11578 (1992).
  CAS PubMed PubMed Central Google Scholar
• Lokker, N. A. et al. Structure–function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. 11, 2503–2510 (1992).
  CAS PubMed PubMed Central Google Scholar
• Cioce, V. et al. Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity. J. Biol. Chem. 271, 13110–13115 (1996).
  CAS PubMed Google Scholar
• Waltz, S. E. et al. Functional characterization of domains contained in hepatocyte growth factor-like protein. J. Biol. Chem. 272, 30526–30537 (1997).
  CAS PubMed Google Scholar
• Matsumoto, K., Kataoka, H., Date, K. & Nakamura, T. Cooperative interaction between α- and β-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses. J. Biol. Chem. 273, 22913–22920 (1998).
  CAS PubMed Google Scholar
• Danilkovitch, A., Miller, M. & Leonard, E. J. Interaction of macrophage-stimulating protein with its receptor. Residues critical for β-chain binding and evidence for independent alpha chain binding. J. Biol. Chem. 274, 29937–29943 (1999).
  CAS PubMed Google Scholar
• Michieli, P. et al. An HGF-MSP chimaera disassociates the trophic properties of scatter factors from their pro-invasive activity. Nature Biotechnol. (in the press).
• Kawaida, K., Matsumoto, K., Shimazu, H. & Nakamura, T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc. Natl Acad. Sci. USA 91, 4357–4361 (1994).
  CAS PubMed PubMed Central Google Scholar
• Tsubouchi, H. et al. Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure. Hepatology 9, 875–881 (1989).
  CAS PubMed Google Scholar
• Yaekashi, M. et al. Simultaneous or delayed administration of hepatocyte growth factor (HGF) equally repress the fibrotic changes in murine lung injury by bleomycin: a morphological study. Am. J. Respir. Clin. Care Med. 156, 1937–1944 (1997).
  Google Scholar
• Ueki, T. et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nature Med. 5, 226–230 (1999).An example of how the beneficial trophic properties of HGF can be exploited for therapeutic applications. In a rat model of lethal liver cirrhosis, transduction of skeletal muscles with the human HGF gene increases HGF plasma levels and produces the complete resolution of fibrosis in the cirrhotic livers, thereby improving the survival rate of rats.
  CAS PubMed Google Scholar
• Kuba, K. et al. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. 60, 6737–6743 (2000).
  CAS PubMed Google Scholar
• Cao, B. et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl Acad. Sci. USA 98, 7443–7448 (2001).
  CAS PubMed PubMed Central Google Scholar
• Abounader, R. et al. In vivo targeting of SF/HGF and c-MET expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 16, 108–110 (2002).
  CAS PubMed Google Scholar
• The Semaphorin Nomenclature Committee. Unified nomenclature for the semaphorin/collapsins. Cell 97, 551–552 (1999).
• Ponzetto, C. et al. c-Met is amplified but not mutated in a cell line with an activated Met tyrosine kinase. Oncogene 6, 553–559 (1991).
  CAS PubMed Google Scholar